Review ArticlePoint-of-Care Testing in Hypercoagulable Conditions Managed With Warfarin A ReviewFaber, Nicholas N. BS; Bulmer, Shanaya C.; Gandhi, Mona A. PharmD; Nagel, Angela K. PharmD, BCPS, BC-ADM Author Information From the Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY. Reprints: Nicholas N. Faber, BS, Wegmans School of Pharmacy, St. John Fisher College, 3690 East Ave, Rochester, NY 14618. E-mail: [email protected]. Authors’ contributions: A.K.N. presented the initial review concept. N.N.F. performed the literature search and wrote the manuscript, with editing support from all authors. The authors declare no conflict of interest. Point of Care: The Journal of Near-Patient Testing & Technology: December 2020 - Volume 19 - Issue 4 - p 101-105 doi: 10.1097/POC.0000000000000215 Buy Metrics Abstract Purpose The aim of this review was to summarize new data on the use of international normalized ratio (INR) point-of-care testing (POCT) devices in hypercoagulable disease states such as antiphospholipid syndrome (APS) and those with left ventricular assist devices (LVADs). Methods PubMed and Google Scholar were searched for keywords relating to warfarin, point-of-care testing, and hypercoagulable conditions. Intensive care unit studies and articles not in English were excluded. Results Four recent studies examining 3 different POCT devices in patients with APS and 2 for patients with LVADs were found. The studies compared devices against laboratory INRs as a standard or against another POCT device to determine device agreeability or bias. Results showed that CoaguChek XS does not correlate well with laboratory INRs in patients with APS but is acceptable in LVAD patients. Coagsense and ProTime InRhythm correlated well with laboratory INR values in APS patients. Conclusions Coagsense and ProTime InRhythm may be acceptable POCT devices to use for APS patients, whereas CoaguChek XS is not acceptable. In LVAD patients, CoaguChek XS is acceptable because it correlates well with laboratory INR values. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.